What Are Psychobiotics? Human Evidence for Mood, Stress and Sleep

Quick Answer: What are psychobiotics, and do they work?

Psychobiotics are probiotic strains studied for possible effects on mood, stress, or sleep through the gut-brain axis. The term was introduced in 2013 for live bacteria that might benefit mental health, and the idea has since broadened to include effects in generally healthy people. Here is the honest state of the evidence: a few specific strains have shown small benefits in human trials, more of the detail comes from animal work, and results do not carry over automatically from one strain to another, to a species-level ingredient, or to a finished multi-ingredient product. Psychobiotics are an area of active research, not a treatment for anxiety, depression, or insomnia. If you are struggling with any of those, speak with a healthcare professional. A probiotic may be a reasonable support for some people, alongside the basics of diet, sleep, and stress management, but it is not a substitute for care.

What Are Psychobiotics?

For a long time, probiotics were thought of as a gut matter, useful for digestion and perhaps immunity. Research over the past decade has explored something more interesting: the gut and brain are in constant, two-way communication through the gut-brain axis.

Out of that work came the idea of psychobiotics. The term was introduced in 2013 to describe live bacteria that, taken in adequate amounts, might benefit people with mental health conditions (Dinan 2013, review). The concept has since been broadened to include effects on mood, stress, and sleep in generally healthy people, mediated through microbial metabolites, neurotransmitter pathways, immune signaling, and the vagus nerve. The key word is studied: this is an active, promising research area, not a finished story.

One point matters throughout this article. Some Next-Microbiome products contain species that have also been investigated in gut-brain research. Evidence from a specific research strain, however, should not be transferred automatically to another strain, to a species-level ingredient, or to a finished multi-ingredient product. The sections below name the strain wherever the evidence is strain-specific.

How Strong Is the Human Evidence?

A useful way to hold the whole field: a 2019 meta-analysis of 34 controlled trials found that probiotics produced small but statistically significant improvements in depression and anxiety scores, while prebiotics did not differ from placebo. The effects were larger in people with a clinical diagnosis, but very few trials studied those groups, so the authors called for more research (Liu 2019, meta-analysis).

So the class-level signal is real but modest, and much of it comes from generally healthy volunteers. From there, the honest approach is to look strain by strain, because that is where the evidence actually lives, and to keep animal findings separate from human ones.

1. Akkermansia muciniphila

Akkermansia muciniphila lives in the intestinal mucus layer and is one of the more studied next-generation bacteria. It is being studied for its interactions with the intestinal mucus environment and with metabolic physiology, and much of the detailed barrier-mechanism evidence so far comes from preclinical research. In a human proof-of-concept trial, a pasteurized form improved insulin sensitivity and some inflammatory markers in overweight adults (Depommier 2019, human). That trial was about metabolic markers, not mood or sleep.

It is worth being clear: Akkermansia is not an established psychobiotic. Inflammatory signaling is one pathway being investigated within the gut-brain field, but it does not explain every case of anxiety, cognitive symptoms, or poor sleep, and a stable gut environment should not be presented as a route to a calmer mind. The accurate position is that Akkermansia is studied for gut-barrier and metabolic physiology, with any gut-brain relevance still preliminary. For the wider picture, see the science on Akkermansia benefits.

2. Clostridium butyricum and Butyrate

Clostridium butyricum is a butyrate producer. Butyrate is a short-chain fatty acid with well-studied roles in the gut barrier, immune balance, and metabolism (Koh 2016, review). Its relationship with sleep is an emerging area studied mostly in animals: butyrate has been linked to more non-REM sleep in rodent work (Szentirmai 2019, animal), which has not been established in people.

So C. butyricum is best understood through its SCFA activity rather than as a proven sleep aid. It appears in Boost Synergy alongside Akkermansia muciniphila. For more on this species, see our overview of Clostridium butyricum.

3. Bifidobacterium infantis and Tryptophan

Bifidobacterium infantis is studied for its role in tryptophan metabolism, the pathway that supplies the raw material for serotonin (O'Mahony 2015, review). Most of the mood-related findings are preclinical or come from irritable bowel syndrome research rather than trials in healthy adults, and it is worth remembering that gut serotonin does not cross into the brain; the brain makes its own.

An important detail on strains: the research strain most often cited is B. infantis 35624. The Akkermansia Chewable contains a species-level B. infantis as part of its multi-strain blend, which is not necessarily that research strain, so the 35624 findings should not be read across to it. This is the strain-specificity point in practice.

4. Bifidobacterium longum: The Strongest Human Signal

Among these strains, Bifidobacterium longum has the most direct human data, and it is still best described as modest. In a trial in healthy volunteers, the specific strain B. longum 1714 reduced perceived stress and cortisol output and produced some cognitive and brain-activity changes (Allen 2016, human). That is a genuine, well-conducted human study, in healthy people, with small effects.

A second strain, B. longum R0175, is often cited for anxiety and mood. The correction here matters: R0175 was studied as a combination with Lactobacillus helveticus R0052, not on its own, and the trial reported lower psychological distress over 30 days in healthy volunteers (Messaoudi 2011, human and animal). These are results for specific strains and, in the R0175 case, a specific combination. They are not automatically the properties of any product that happens to contain a B. longum.

5. Lactobacillus rhamnosus JB-1

Lactobacillus rhamnosus JB-1 is one of the most cited names in this field, and it is also the clearest lesson in reading the evidence carefully. In mice, JB-1 altered GABA receptor expression and reduced anxiety-like behavior, and those effects disappeared when the vagus nerve was cut, a striking demonstration of gut-brain communication (Bravo 2011, animal).

The nuance is essential. When the same strain was tested in a trial of healthy men, it produced no effect on stress, mood, sleep quality, the HPA stress response, inflammation, or cognition (Kelly 2017, human). The promising mouse findings did not translate. So JB-1 is a good example of why animal results are a starting point, not a conclusion, and why JB-1 evidence cannot be read across to a generic Lactobacillus rhamnosus ingredient.

Psychobiotic Evidence by Strain

A quick guide to where the evidence stands for each strain, and what kind of evidence it is.

Human Versus Preclinical Evidence: A Quick Hierarchy

Not all evidence carries the same weight, and psychobiotic claims are easy to overstate if the layers are blurred. A simple hierarchy helps:

• Randomized controlled trials in the relevant population are the strongest evidence. There are still few of these for mood, stress, and sleep, and most are in healthy volunteers rather than people with a diagnosis.

• Small human trials in healthy volunteers (like the B. longum 1714 study) are useful signals but show small effects and need replication.

• Animal studies (like the JB-1 mouse work) reveal possible mechanisms, but as JB-1 showed, they do not always translate to people.

• Laboratory and mechanistic work explains how something might act, without showing a real-world benefit.

Two rules sit on top of all of this: evidence is strain-specific, and a finished multi-ingredient product has its own evidence only if that exact formulation was tested.

What the Class-Wide Evidence Can and Cannot Tell Us

Pooled across many trials, probiotics show small, real improvements in mood and anxiety measures, with larger effects hinted at in clinically diagnosed groups that remain understudied (Liu 2019). What the class-wide evidence cannot do is tell you that a particular product will work for a particular person. Trials differ in strain, dose, formulation, population, duration, and outcome measure, and that variation is exactly why results are inconsistent. The reasonable takeaway is cautious optimism about the field, paired with modest expectations for any single supplement.

A Note on Mental Health Care

Psychobiotics are not a treatment for anxiety, depression, or insomnia, and nothing here is a substitute for professional care. If you are dealing with persistent low mood, anxiety, or sleep problems that affect your daily life, please talk with a qualified healthcare professional. Evidence-based treatments exist, and a probiotic, at best, is a possible complement to them for some people, not a replacement. If you ever feel unsafe or in crisis, contact local emergency services or a crisis line in your area.

A Personal Note

When I started working on the gut-brain axis, I expected a tidy set of pathways. What I found instead is a field that is genuinely hard, and genuinely interesting, precisely because the body does not read like a simple circuit. A strain that changes behavior in mice can do nothing measurable in people. A combination can outperform its parts. Small human trials point one way, and the next study complicates the picture. That is not a weakness of the science; it is what honest, early-stage research looks like.

Several individual strains and microbiome pathways discussed in this field have been investigated in human trials, while others remain supported primarily by preclinical research. Those studies should not be treated as trials of any finished Next-Microbiome product unless the exact formulation was tested. What keeps me interested is not a promise of quick fixes, but the slow, real progress of understanding how microbes and the nervous system talk to each other.

Where Next-Microbiome's Formulas Fit

Next-Microbiome builds formulas around several of the species discussed here. Akkermansia Chewable pairs Akkermansia muciniphila with Bifidobacterium infantis and lactobacilli, and Boost Synergy combines Akkermansia muciniphila with Clostridium butyricum, HMO, and ashwagandha.

To be accurate about what that means: containing a species that appears in gut-brain research is not the same as having been tested, as a finished product, for mood, stress, or sleep. Treat these as microbiome-support formulas that fit alongside a whole-food, fiber-rich diet, regular sleep, and stress management, not as treatments for a mental health or sleep condition. If you are pregnant, nursing, managing a condition, or taking medication, check with a clinician first.

The Bottom Line

Psychobiotics are a real and promising research area with variable evidence. A few specific strains have shown small benefits in human trials, more of the detail comes from animal work, and the results are strain-specific rather than properties of a whole category or a whole product. That is an honest and still-encouraging place for the science to be.

Psychobiotic studies use different strains, doses, populations, and durations, so there is no validated universal timeline for mood, stress, or sleep effects. If you decide to try a probiotic for general wellbeing, give it a fair, consistent trial alongside the basics that have stronger evidence, good sleep habits, a varied diet, movement, and stress management, and keep your expectations proportionate to what the research actually shows.

Frequently Asked Questions About Psychobiotics

1. What are psychobiotics?

Psychobiotics are probiotic strains studied for possible effects on mood, stress, or sleep through the gut-brain axis. The term was coined in 2013 for live bacteria that might benefit mental health, and it now also covers effects studied in generally healthy people. They are a research area, not an approved treatment.

2. What are some examples of psychobiotics?

The most studied named strains include Bifidobacterium longum 1714 (stress and cortisol in healthy volunteers), the combination of Lactobacillus helveticus R0052 with Bifidobacterium longum R0175 (psychological distress), and Lactobacillus rhamnosus JB-1 (anxiety-like behavior in mice, though a human trial found no effect). Each result belongs to that specific strain or combination.

3. Can psychobiotics help with stress resilience?

Some specific strains have shown small reductions in perceived stress or cortisol in healthy volunteers, and pooled analyses show modest average effects. The evidence is strongest for particular strains rather than for probiotics in general, and it does not amount to a treatment for a stress or anxiety disorder. For persistent stress, professional support and evidence-based strategies come first.

4. Is Lactobacillus rhamnosus JB-1 a proven psychobiotic?

Not in humans. JB-1 reduced anxiety-like behavior in mice through the vagus nerve, but a randomized trial in healthy men found no effect on stress, mood, sleep, or the stress-hormone response. It is a good example of why promising animal findings need human confirmation, and why results for one strain do not transfer to a generic ingredient.

5. Is Bifidobacterium infantis a psychobiotic?

It is studied as one. B. infantis is linked to tryptophan and serotonin metabolism, but most mood-related findings are preclinical or come from IBS research. The commonly cited research strain is 35624; a species-level B. infantis in a supplement is not necessarily that strain, so its specific findings should not be assumed to carry over.

6. Can psychobiotics support mood?

Pooled human data show small, statistically significant improvements in mood and anxiety scores for probiotics, with larger effects hinted at in clinically diagnosed groups that remain understudied. That supports cautious interest, not the idea that a supplement treats depression. If mood is affecting your life, speak with a healthcare professional.

7. What foods and habits support the gut-brain axis?

A varied, whole-food diet rich in fiber and plants, fermented foods if you tolerate them, regular sleep, physical activity, and stress management all support gut and general health, and these habits have stronger and broader evidence than any single probiotic. A probiotic, if you choose one, sits on top of that foundation rather than replacing it.

8. How long do psychobiotics take to work?

There is no validated universal timeline. Studies use different strains, doses, populations, and durations, and outcomes vary. If you try a probiotic for general wellbeing, use it consistently for a reasonable period and judge it against the basics that have stronger evidence, rather than expecting a fixed result by a set number of weeks.

Scientific References

1. Dinan TG, Stanton C, Cryan JF.
   Psychobiotics: A Novel Class of Psychotropic
   Biological Psychiatry 2013;74(10):720-726
   doi:10.1016/j.biopsych.2013.05.001 (Review; origin of the term)

2. Liu RT, Walsh RFL, Sheehan AE.
   Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials
   Neuroscience and Biobehavioral Reviews 2019;102:13-23
   doi:10.1016/j.neubiorev.2019.03.023 (Meta-analysis of controlled trials)

3. Allen AP, Hutch W, Borre YE, et al.
   Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers
   Translational Psychiatry 2016;6(11):e939 
   doi:10.1038/tp.2016.191 (Human study)

4. Messaoudi M, Lalonde R, Violle N, et al.
   Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects 
   British Journal of Nutrition 2011;105(5):755-764
   doi:10.1017/S0007114510004319 (Animal and human; combination formulation)

5. Bravo JA, Forsythe P, Chew MV, et al.
   Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve
   Proceedings of the National Academy of Sciences 2011;108(38):16050-16055
   doi:10.1073/pnas.1102999108 (Animal study; L. rhamnosus JB-1)

6. Kelly JR, Allen AP, Temko A, et al.
   Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects
   Brain, Behavior, and Immunity 2017;61:50-59 
   doi:10.1016/j.bbi.2016.11.018 (Human study; null result)

7. O'Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF.
   Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
   Behavioural Brain Research 2015;277:32-48
   doi:10.1016/j.bbr.2014.07.027 (Review)

8. Depommier C, Everard A, Druart C, et al.
   Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
   Nature Medicine 2019;25(7):1096-1103 
   doi:10.1038/s41591-019-0495-2 (Human randomized pilot; metabolic markers)

9. Szentirmai E, Millican NS, Massie AR, Kapas L.
   Butyrate, a metabolite of intestinal bacteria, enhances sleep
   Scientific Reports 2019;9:7035 
   doi:10.1038/s41598-019-43502-1 (Animal study)

10. Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F.
    From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
    Cell 2016;165(6):1332-1345
    doi:10.1016/j.cell.2016.05.041 (Review)

Written by Ali Rıza Akın

Microbiome Scientist, Author & Founder of Next-Microbiome

Ali Rıza Akın is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation.

His work focuses on how microbial ecosystems interact with human physiology, including:

• Gut barrier function and intestinal permeability

• Mucus-associated microbiota (Akkermansia-related systems)

• Oral–gut microbiome axis

• Short-chain fatty acids (SCFAs) and metabolic signaling

• Circadian rhythm–microbiome interactions

• Clinical Research Contributions

He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including:

Active Ulcerative Colitis (Inflammatory Bowel Disease)

Hyperoxaluria (Oxalate Metabolism Disorder)

Microbiome-driven gut health and inflammatory conditions

These studies were part of broader clinical development programs evaluating microbiome-based approaches. His contributions focused on the early-stage scientific and translational pipeline, including strain discovery, functional optimization, and multi-strain formulation design.

Scientific Contributions:

Ali Rıza Akın is the discoverer of Christensenella californii, a bacterial species associated with microbiome diversity and metabolic health.

He is a contributing author to scientific publications and Bacterial Therapy of Cancer (Springer), and the author of Bakterin Kadar Yaşa: İçimizdeki Evren: Mikrobiyotamız.

Approach:

His work emphasizes evidence-based microbiome science, long-term safety, and a systems-based understanding of how microbes influence human health.

Review and Sources

This article is written and reviewed by a microbiome scientist and is based on the peer-reviewed studies listed in the References. Human, animal, and review evidence are labeled throughout, and strains are named where the evidence is strain-specific, so readers can weigh each claim. It is reviewed periodically against current research.

Medical Disclaimer

This content is for educational and informational purposes only and is not medical advice. It does not diagnose, treat, cure, or prevent any disease or condition, including anxiety, depression, or insomnia. Psychobiotics are an area of ongoing research, and dietary supplements are not a substitute for professional mental health or medical care or for evidence-based treatment. Do not start, stop, or change any treatment based on this content. Speak with a qualified healthcare professional about persistent mood, stress, or sleep problems, and before starting any new supplement, especially if you are pregnant, nursing, managing a health condition, or taking medication. If you feel unsafe or in crisis, contact local emergency services or a crisis line in your area.

Last reviewed: August 2026